Femme et Homme
- | Pays :
- United Kingdom
- Australia
- Russian Federation
- | Organes : -
- | Spécialités : -
Extrait
This will be a double-blind, placebo controlled cross-over study. After enrolment and initial assessments, subjects will receive oral SB681323 or matching placebo for 14 days. SB681323 will be administered twice daily at a total daily dose of 7.5mg. Sufficient numbers of patients will be recruited to obtain 40 evaluable patients
Critère d'inclusion
- Pain, Neuropathic ,neuropathic pain ,Nerve Trauma